Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF

2002148 citationsJournal Article

Authors

Nicolas Margot · Gilead Sciences (United States)

Erica Isaacson

Abstract

Adding tenofovir DF 300 mg to an existing regimen in patients with ongoing viral replication and a wide range of genotypic resistance patterns resulted in significant and durable HIV-1 RNA reductions. In addition, there was a low incidence of genotypic or phenotypic resistance to tenofovir DF arising during 48 weeks of therapy.

Topics & Keywords

HIV/AIDS drug development and treatment HIV Research and Treatment HIV/AIDS Research and Interventions

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: AIDS

Volume 16, Issue 9, pp. 1227-1235

DOI: 10.1097/00002030-200206140-00004

Field-Weighted Citation Impact: 9.29